Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.8352W HIGH $8.54
Volume
170.09 K
Value Traded
2.97 M
Short % Float
9.07%
-3.25%Week
+6.17%1 Month
-8.91%3 Month
-25%6 Month
-33.71%5 Year
-6.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
234.96 M
EPS (TTM)
-0.04
P/E Ratio
-
Ent. Value
117.72 M
Total Shares
71.85 M
Float Shares
41.13 M
Insiders
42.75%
Institutions
48.79%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SIGA Catalyst Timeline
Dated clinical, regulatory and corporate events for SIGA Technologies Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SIGA Technologies Inc.
285Total events
1Upcoming
59Tier-1 (high impact)
2004 to 2026Coverage
Upcoming catalysts 1
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
Event history 50
▲Product LaunchTPOXXApprovedPost-Market
Expected delivery of oral and IV TPOXX to U.S. Government and international customer
orthopoxvirus infectionssource ↗
▲Product LaunchTPOXXApprovedPost-Market
Delivered $24M IV TPOXX to U.S. strategic national stockpile under 19C contract
smallpoxsource ↗
▲Product LaunchTPOXXApprovedPost-Market
Delivered $24 million IV TPOXX to U.S. strategic national stockpile under 19C contract
smallpoxsource ↗
◆Quarterly UpdateCorporate
First-quarter 2026 financial results release and business update call
◆Timing GuidanceTPOXXApprovedPresentation
Expects to deliver >$35M of oral and IV TPOXX to U.S. Government and international customer in Q2-Q3 2026
orthopoxvirus (smallpox)source ↗
▲Product LaunchTPOXXApprovedPost-Market
Expected delivery of oral and IV TPOXX to U.S. Government and international customer
orthopoxvirus infectionssource ↗
●Quarterly UpdateCorporate
Special cash dividend of $0.60 per share declared on March 26, 2026
▲Partnership / LicenseTPOXXApprovedCorporate
Received $13 million procurement order from Asia Pacific customer for oral TPOXX
orthopoxvirus infectionsource ↗
▲Milestone PaymentTPOXXApprovedCorporate
Awarded $27M incremental development funding under BARDA 19C contract for TPOXX pediatric program and manufacturing
smallpoxsource ↗
▲Product LaunchTPOXXApprovedPost-Market
Recorded $53M oral TPOXX and $26M IV TPOXX sales to Strategic National Stockpile
smallpoxsource ↗
●Quarterly UpdateCorporate
SIGA reports financial results for three and twelve months ended December 31, 2024
▼Interim AnalysisTecovirimatApprovedTrial
Interim analysis of STOMP trial shows tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox
mpoxsource ↗
▼Trial DiscontinuedTecovirimatApprovedTrial
Enrollment stopped in randomized and open-label arms of STOMP trial following DSMB recommendation
mpoxsource ↗
●Quarterly UpdateCorporate
Reported financial results for three and nine months ended September 30, 2024
▲Quarterly UpdateTPOXXApprovedCorporate
Received $112.5 million order for oral TPOXX under BARDA contract
smallpoxsource ↗
▼Topline ReadoutTecovirimatApprovedClinical Data
Topline results from PALM 007 study of tecovirimat in mpox
mpoxsource ↗
▼Primary Endpoint MissedTPOXXApprovedClinical Data
NIAID announced TPOXX® clinical trial failed to meet primary endpoint
Mpoxsource ↗
●Quarterly UpdateCorporate
SIGA reports financial results for three and six months ended June 30, 2024
▲Product LaunchTPOXXApprovedPost-Market
U.S. government exercises procurement option for $113M of oral TPOXX
orthopoxvirussource ↗
▲Product LaunchTPOXXApprovedPost-Market
Start of IV TPOXX delivery under new order expected in 2024
smallpoxsource ↗
▲Other Regulator MilestoneTPOXXApprovedEx-US Regulatory
European Commission signs joint procurement framework contract for oral TPOXX
smallpoxsource ↗
▲Timing GuidanceTPOXXApprovedPresentation
Target delivery of approximately $113 million oral TPOXX to U.S. strategic national stockpile in Q4 2023
smallpoxsource ↗
▲Product LaunchTPOXXApprovedPost-Market
U.S. Government exercises procurement options for oral and IV TPOXX
smallpoxsource ↗
▲Supply DisruptionTPOXXApprovedCMC / Inspection
U.S. government orders for oral and IV TPOXX
smallpoxsource ↗
◆Product LaunchTPOXXApprovedPost-Market
Targeting ~$113M oral TPOXX deliveries to SNS in 2023
smallpoxsource ↗
◆Product LaunchTPOXXApprovedPost-Market
Product deliveries of IV TPOXX targeted for 2023
smallpoxsource ↗
▲Timing GuidancePresentation
Target full year 2023 pre-tax operating income of $90-100 million
Past FDA Catalysts and PDUFA Decisions
How SIGA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-05-18 | Tpoxx (tecovirimat) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$4M
Pipeline Value
$54M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 78%
Micro Cap(rank 513 of 658)
Percentile Rank
SIGA Technologies Inc. faces pipeline headwinds (27/100), with $16M risk-adjusted pipeline value, led by ST-246 Days 1- 3 in Orthopoxviral Disease (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $53.7M x 1.0 = $54M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| TPOXX | $45M | $174M | -74.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ST-246 Days 1- 3 Small moleculeCompletedNCT00728689 | Orthopoxviral Disease | Phase 1 | COMPLETED | 12 | Oct 1, 2008 |
Clinical Trial Results
Readouts, endpoints and source filings for every SIGA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Tecovirimat | mpox | 2024-12-10 | did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placeboRead More | Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Marshall Joseph W IIIDirector | Option | 24,116 253,758 held | $0.00 | 06/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SIGA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SIGA for Q2 2026. | ||||
SIGA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SIGA ranks across every disease it competes in
Competitive Position is a premium feature
See how SIGA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSIGA News
SIGASIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
SIGA Technologies reported financial results for the second quarter of 2026, highlighting $37 million in TPOXX sales. The company successfully delivered both IV and oral formulations of TPOXX to various customers, including the U.S. strategic national stockpile. A conference call is scheduled for further updates on their business activities.
Read more →SIGASIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
SIGA Technologies, Inc. will host a business update call on August 6, 2026, at 4:30 P.M. ET to discuss its second-quarter financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A live webcast will be accessible on the company's website, and a replay will be available for two weeks.
Read more →SIGASIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
SIGA Technologies, Inc. reported its financial results for Q1 2026, highlighting expectations to deliver over $35 million of TPOXX to various customers. The CEO emphasized the company's strategy to secure new contracts to enhance business growth. However, SIGA faces several risks, including potential delays in contract performance and challenges in the international market.
Read more →SIGASIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
SIGA Technologies, Inc. will host a business update call on May 7, 2026, to discuss its first-quarter financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Participants can join via phone or webcast, with a replay available for two weeks. SIGA focuses on developing medicines for infectious diseases.
Read more →SIGASIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies has announced a special cash dividend of $0.60 per share, consistent with last year's dividend. The payment is scheduled for April 23, 2026, to shareholders on record by April 7, 2026. CEO Diem Nguyen emphasized the company's commitment to shareholder value and public health preparedness amid geopolitical challenges.
Read more →SIGASIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
SIGA Technologies, Inc. has reported its financial results for the year ended December 31, 2025. The company generated $88 million in product revenues but experienced a net loss of $5.4 million for the fourth quarter. Despite the challenges, SIGA secured $27 million in government funding and received a procurement order worth $13 million for its oral TPOXX product. The company aims to strengthen its position as a reliable partner to governments for future revenues.
Read more →SIGA▼ -5%on this news
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
SIGA Technologies, Inc. has announced a business update call scheduled for March 10, 2026, at 4:30 PM ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire, providing insights into the company's 2025 financial results. A live webcast will be available, along with a replay for two weeks afterward.
Read more →SIGA▼ -20%on this news
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
SIGA Technologies, Inc. reported strong financial results for the first nine months of 2025, achieving $86 million in product revenues and $33 million in pre-tax operating income. The company is focused on expanding its partnerships with government entities to secure future procurement contracts. A conference call is scheduled to discuss their business updates.
Read more →SIGASIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
SIGA Technologies, Inc. will host a business update call on November 6, 2025, at 4:30 PM ET to discuss its third-quarter results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Participants can join via phone or a live webcast, with a replay available afterward. SIGA is known for its antiviral product TPOXX, aimed at treating smallpox and other orthopoxvirus infections.
Read more →SIGASIGA Reports Financial Results for Three and Six Months Ended June 30, 2025 NEW YORK, August 5, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a
SIGA Technologies, Inc. reported robust financial results for the second quarter and six months ending June 30, 2025. The company generated substantial revenues from its product, TPOXX, totaling approximately $79.1 million, alongside additional development funding from BARDA totaling $27 million. These results underscore SIGA's strong business model and the increasing demand for TPOXX, particularly for uses in treating smallpox. Furthermore, SIGA declared a special dividend, reflecting positive cash flow and shareholder value.
Read more →SIGASIGA Reports Financial Results for Three Months Ended March 31, 2025
SIGA Technologies, Inc. has reported its financial results for the first quarter ended March 31, 2025, showing a decrease in total revenues compared to the same period last year. The company expressed confidence in upcoming sales from Strategic National Stockpile orders, expecting to fulfill a $70 million order by Q3. Meanwhile, SIGA declared a special cash dividend of $0.60 per share, highlighting financial maneuvers despite reporting an operating and net loss. The conference call and webcast scheduled will provide further details on the company’s business strategy and operations.
Read more →SIGASIGA Appoints Retired General John M. Keane to its Board of Directors
SIGA Technologies has appointed Retired General John M. Keane to its Board of Directors. General Keane brings extensive military and national security experience, which SIGA believes will enhance its efforts in biodefense. His insights are expected to be valuable as the company aims to expand its antiviral reach and collaborate with government stakeholders.
Read more →SIGASIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024
SIGA Technologies, Inc. reported robust financial results for the year ended December 31, 2024, achieving $133 million in product sales and a pre-tax operating income of $70 million. This marks the second consecutive year of product revenue growth for the company, illustrating its financial strength. As the company moves into 2025, SIGA focuses on sustainable growth supported by significant outstanding procurement orders. The CEO emphasized the company's commitment to expanding their impact in combating infectious diseases.
Read more →SIGA▼ -6.8%on this news
Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate
SIGA's interim results from the STOMP clinical trial revealed that their antiviral treatment tecovirimat failed to improve lesion resolution in patients with mild to moderate mpox compared to a placebo. Following these findings, the study's Data Safety and Monitoring Board recommended halting enrollments in both the randomized and open-label arms of the trial. Approximately 75% of participants received treatment after more than five days of symptom onset, which may have affected the outcomes. While the safety profile of tecovirimat appeared similar to placebo, ongoing analysis of primary endpoints remains incomplete.
Read more →SIGASIGA Reports Financial Results for Three and Nine Months Ended
SIGA Technologies reported financial results for the three and nine months ending September 30, 2024, showcasing a significant increase in net income and product sales. The company secured $122 million in orders, including a major contract with BARDA and the Department of Defense. With approximately $146 million in outstanding procurement orders, SIGA anticipates robust revenue growth in the upcoming quarters. However, they face uncertainty with potential contract modifications and market challenges.
Read more →SIGA▼ -19.6%on this news
Topline Results from PALM 007 Study of SIGA'S Tecovirimat in Treatment of Mpox Released Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to
The PALM 007 study results showed that SIGA's tecovirimat did not achieve statistical significance in improving lesion resolution for mpox patients. However, the drug demonstrated potential benefits for severely ill patients who received treatment early. The safety profile of tecovirimat was comparable to placebo. Further analysis is necessary to refine the understanding of treatment effectiveness and to plan future trials.
Read more →SIGA▼ -7.4%on this news
SIGA Reports Financial Results for Three and Six Months Ended
SIGA Technologies, Inc. reported strong financial results for the three and six-month periods ending June 30, 2024, with total revenues reaching $21 million, driven largely by $18 million in IV TPOXX sales to the U.S. Government. The company reported a substantial increase in product revenues, totaling $45 million for the first half of the year, a marked improvement compared to prior year figures. SIGA is focused on diversifying its revenue base and advancing its clinical programs while enhancing shareholder value. Looking ahead, the company plans to negotiate new contracts with the U.S. Government and promote public health initiatives.
Read more →SIGASIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX Exercise of Procurement Option under Current Contract Reflects Continuing Action to Enhance Orthopoxvirus Preparedness NEW YORK (GLOBE NEWSW
SIGA Technologies, Inc. announced a $113 million procurement order from the U.S. Department of Health and Human Services for oral TPOXX treatment courses. This order aims to enhance national preparedness against orthopoxvirus threats and reflects SIGA's ongoing commitment to public health. The announcement highlights SIGA's leadership in the development of countermeasures against serious infectious diseases. However, the company faces various risks related to contract fulfillment and market competition.
Read more →About SIGA Technologies Inc.
Headquarters31 EAST 62ND STREET, NEW YORK, NY, 10065
BIOPHARMAWATCH ELITE PLUS
Trade the next SIGA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime